



CONSENSUS CONFERENCE FOR THE METABOLIC DIAGNOSIS AND MEDICAL PREVENTION OF CALCIUM NEPHROLITHIASIS AND ITS SYSTEMIC MANIFESTATIONS (& Educational course on renal stone disease)

Rome (Italy), March 26 – 28, 2015

Organized by
DIVISION OF NEPHROLOGY AND DIALYSIS
COLUMBUS-GEMELLI UNIVERSITY HOSPITAL
UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROME, ITALY

Promoted by



FONDAZIONE
INTERNAZIONALE
MENARINI

Palazzo Brancaccio

Viale del Monte Oppio, 7 - Largo Brancaccio, 82/a

Thursday, March 26, 2015 - Afternoon

02.00 p.m. - 03.45 p.m. Reception

03.45 p.m. - 04.00 p.m. **Welcome address**
G. Gambaro (Rome, I) and **E. Croppi** (Florence, I)

Session I - The clinical phenotypes of the stone patients

Chair: **O.W. Moe** (Dallas, USA)

04.00 p.m. - 04.40 p.m. **F.L. Coe** (Chicago, USA)
Idiopathic calcium stone patient: how do we define it?
Calcium Oxalate stones, Brushite stones, Apatite stones (the phenotype and how to Dx)

04.40 p.m. - 05.00 p.m. **D. Fuster** (Berne, CH)
Idiopathic calcium stones: separation from Renal Tubular Acidosis
Is there an incomplete RTA? What is it?

05.00 p.m. - 05.30 p.m. **O.W. Moe** (Dallas, USA)
Hyperuricosuric calcium stone formers
Is there a rationale in using hypouricemic drugs?

Session II - the risk of mbd and ckd in stone formers

Chair: **D.A. Bushinsky** (Rochester, USA)

05.30 p.m. - 05.45 p.m. **G. Gambaro** (Rome, I)
Which stone patient is at high risk of CKD?

05.45 p.m. - 06.00 p.m. **D.A. Bushinsky** (Rochester, USA)
Which stone patient is at high risk of bone disease?
What therapies are available? The conventional interventions for osteoporosis may or may not work or even be dangerous in stone patients

06.00 p.m. Welcome cocktail

Friday, March 27, 2015 – Morning

Session III - The diagnostic work-up in stone patients

Chair: **D. Milliner** (Rochester, USA)

08.30 a.m. - 9.15 a.m. **E. Worcester** (Chicago, USA)
Detection of systemic causes: what is the best evaluation?

09.15 a.m. - 09.40 a.m. **J. Lieske** (Rochester, USA)
Detection of causes in idiopathic
SF 24 hour testing: how important, how many?

09.40 a.m. - 10.20 a.m. **M. Marangella** (Turin, I)
Can we measure metastability and urinary inhibitors and promoters for practical use?
Is supersaturation a guide to stone treatment - what are the goals. What is the best intermediate outcome measure when SS is not available (as in most of Europe). Disorders that promote supersaturation - can be measured? Importance for treatment outcome. Importance for predicting comorbidities? Importance for future research? Importance for planning trials?

10.20 a.m. - 10.40 a.m. **D. Milliner** (Rochester, USA)

Do urine crystals really tell us anything of clinical value?

10.40 a.m. - 11.10 a.m. *Coffee break*

Chair: **J.C. Williams** (Indianapolis, USA)

11.10 a.m. - 11.40 a.m. **J.E. Lingeman** (Indianapolis, USA)
Use of surgical observations for diagnosis
Stones not otherwise visible; Papillary appearance as a guide to Idiopathic stones and secondary causes of stones

11.40 a.m. - 12.10 a.m. **J.C. Williams** (Indianapolis, USA)
Crucial nature of stone analysis
Including stone morphology, Quality of laboratories; role of DE CT

Session IV - Urologist-nephrologist cross-talk

Chair: **G. Capasso** (Naples, I)

12.10 a.m. - 12.25 a.m. **N. Buchholz** (London, UK)
What the urologist asks the nephrologist
Developing a guideline for interaction and joint follow-up

12.25 a.m. - 12.40 p.m. **E. Croppi** (Florence, I)
What the nephrologist asks the urologist
Developing a guideline for interaction and joint follow-up

01.00 p.m. - 02.00 p.m. *Lunch*

Session V – Treatment: Who should undergo prevention of renal stones?

Chair: **Ph. Jaeger** (Geneve/London, UK)

02.00 p.m. - 02.30 p.m. **G.M. Preminger** (Durham, USA)
Activity of stone disease; recurrent vs. single stone formers
Who is recurrent? Does the definition of activity rely only on stone recurrence and/or growth and/or need of surgeries. How to gauge formation. Should we consider also urinary and/or systemic abnormalities?

Friday, March 27, 2015 – Afternoon

Session VI – TREATMENT: Prevention of renal stones

Chair: **D. Goldfarb** (New York, USA)

02.30 p.m. - 03.00 p.m. **P. Strazzullo** (Naples, I)
Do any of the diet treatments prevent CaOx stones? Low purine; low protein; low sodium; low oxalate?

03.00 p.m. - 03.30 p.m. **R. Siener** (Bonn, D)
Is any special beverage likely to matter apart from being a way to provide water?

03.30 p.m. - 04.00 p.m. **K. Sakhaee** (Dallas, USA)

When to use citrate?
Is citrate harmful or beneficial for calcium phosphate stones? Conversion between stone types, is it a problem?

04.00 p.m. - 04.30 p.m. *Coffee break*

Chair: **G.C. Curhan** (Boston, USA)

04.30 p.m. - 05.00 p.m. **B. Hess** (Zurich, CH)
When to use thiazides or oral phosphate?

05.00 p.m. - 05.30 p.m. **I.P. Heilberg** (San Paolo, BR)
How do we follow patients?
Metabolic flu, radiologic flu

PANEL MEETING (CLOSED SESSION)

Works in small panels for the development of the position statement – Friday, March 27, 2015 from 05.30 p.m. to 07.30 p.m.

WORKING PANELS (9 panels)

Saturday, March 28, 2015 – Morning

Chair: **J. Desai** (Ahmedabad, India)

08.30 a.m. - 09.30 a.m. **J.M. Reis Santos** (Lisbon, PT)
Urological treatment of stones: a moving scenario (educational)

09.30 a.m. - 10.00 a.m. **K. Sarica** (Istanbul, T)
Guidelines for the urological treatment of stones: an overview (educational)

10.00 a.m. - 10.30 a.m. *Coffee break*

Chair: **Z. Kirkali** (Bethesda, USA)

10.30 a.m. - 12.30 a.m. **Presentations of proposals for the position paper and plenary discussion**

12.30 a.m. - 12.45 a.m. *Concluding remarks*

12.45 a.m. - 02.00 a.m. *Farewell lunch*

PANEL MEETING (CLOSED SESSION)

Works in small panels for the development of the position statement Saturday, March 28, 2015 from 08.30 a.m. to 10.30 a.m.

WORKING PANELS (9 panels)

Under the Auspices of



European Renal Association/European
Dialysis and Transplantation Association
ERA-EDTA



European Association of Urology
EAU-EULIS

Co-Presidents of the Meeting

Giovanni Gambaro
Division of Nephrology
Columbus-Gemelli University Hospital
Università Cattolica del Sacro Cuore
Rome, Italy

Steering Committee

**Fredric L. Coe, Emanuele Croppi, Giovanni Gambaro,
James E. Lingeman, Orson W. Moe, Elaine Worcester**

Emanuele Croppi
A.S.L. 10 Florence
Florence, Italy

Promoted by

Fondazione Internazionale Menarini
Edificio L – Strada 6
Centro Direzionale Milanofiori
20089 Rozzano (Milan, Italy)
Phone: +39 02 55308110
Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
Http://www.fondazione-menarini.it

Organizing Secretariat - Provider

AVEC S.r.l. - Incentive Paintings
Angela Volpe / Claudia Cislighi
Via Lavoratori Autobianchi, 1
c/o Polo Tecnologico Brianza - Edificio 9 - Ufficio 14
I-20832 Desio (MB), Italy
Phone: +39 0362 581579 – Fax: +39 0362 544211
E-mail: angela.volpe@avec-eventi.com /
claudia.cislighi@avec-eventi.com